Patient leaflet - ERLOTINIB AMAROX 25 MG FILM-COATED TABLETS
1. what erlotinib is and what it is used for
Erlotinib contains the active substance erlotinib. Erlotinib is a medicine used to treat cancer by preventing the activity of a protein called epidermal growth factor receptor (EGFR). This protein is known to be involved in the growth and spread of cancer cells.
Erlotinib is indicated for adults. This medicine can be prescribed to you if you have non-small cell lung cancer at an advanced stage. It can be prescribed as initial therapy or as therapy if your disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations. It can also be prescribed if previous chemotherapy has not helped to stop your disease.
This medicine can also be prescribed to you in combination with another treatment called gemcitabine if you have cancer of the pancreas at a metastatic stage.
2. what you need to know before you take erlotinibdo not take erlotinib: if you are allergic to erlotinib or any of the ingredients of this medicine (listed in section 6).
Warnings and precautions:
- if you are taking other medicines that may increase or decrease the amount of erlotinib in your blood or influence its effect (for example antifungals like ketoconazole, protease inhibitors, erythromycin, clarithromycin, phenytoin, carbamazepine, barbiturates, rifampicin, ciprofloxacin, omeprazole, ranitidine, St. John's Wort or proteasome inhibitors), talk to your doctor. In some cases these medicines may reduce the efficacy or increase the side effects of Erlotinib and your doctor may need to adjust your treatment. Your doctor might avoid treating you with these medicines while you are receiving Erlotinib.
- if you are taking anticoagulants (a medicine which helps to prevent thrombosis or blood clotting e.g. warfarin), Erlotinib may increase your tendency to bleed. Talk to your doctor, he will need to regularly monitor you with some blood tests.
- if you are taking statins (medicines to lower your blood cholesterol), Erlotinib may increase the risk of statin related muscle problems, which on rare occasions can lead to serious muscle breakdown (rhabdomyolysis) resulting in kidney damage, talk to your doctor.
- if you use contact lenses and/or have a history of eye problems such as severe dry eyes, inflammation of the front part of the eye (cornea) or ulcers involving the front part of the eye, tell your doctor.
See also below “Other medicines and Erlotinib”
You should tell your doctor:
- if you have sudden difficulty in breathing associated with cough or fever because your doctor may need to treat you with other medicines and interrupt your Erlotinib treatment;
- if you have diarrhoea because your doctor may need to treat you with anti-diarrhoeal (for example loperamide);
- immediately, if you have severe or persistent diarrhoea, nausea, loss of appetite, or vomiting because your doctor may need to interrupt your Erlotinib treatment and may need to treat you in the hospital;
- if you have severe pain in the abdomen, severe blistering or peeling of skin. Your doctor may need to interrupt or stop your treatment;
- if you develop acute or worsening redness and pain in the eye, increased eye watering, blurred vision and/or sensitivity to light, please tell your doctor or nurse immediately as you may need urgent treatment (see Possible Side Effects below).
- if you are also taking a statin and experience unexplained muscle pain, tenderness, weakness or cramps. Your doctor may need to interrupt or stop your treatment.
See also section 4 “Possible side effects”.
Liver or kidney disease
It is not known whether Erlotinib has a different effect if your liver or kidneys are not functioning normally. The treatment with this medicine is not recommended if you have a severe liver disease or severe kidney disease.
Glucuronidation disorder like Gilbert's syndrome
Your doctor must treat you with caution if you have a glucuronidation disorder like Gilbert's syndrome.
Smoking
You are advised to stop smoking if you are treated with Erlotinib as smoking could decrease the amount of your medicine in the blood.
Children and adolescents
Erlotinib has not been studied in patients under the age of 18 years. The treatment with this medicine is not recommended for children and adolescents.
Other medicines and Erlotinib
Tell your doctor or pharmacist if you are taking, have recently taken any other medicines or might take any other medicines.
Erlotinib with food and drink
Do not take Erlotinib with food. See also section 3 ‚How to take Erlotinib‘.
Pregnancy and breast-feeding
Avoid pregnancy while being treated with Erlotinib. If you could become pregnant, use adequate contraception during treatment, and for at least 2 weeks after taking the last tablet.
If you become pregnant while you are being treated with Erlotinib, immediately inform your doctor who will decide if the treatment should be continued.
Do not breast-feed if you are being treated with Erlotinib, and for at least 2 weeks after taking the last tablet.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Erlotinib has not been studied for its possible effects on the ability to drive and use machines but it is very unlikely that your treatment will affect this ability.
Hypersensitivity
Erlotinib contains a sugar called lactose monohydrate.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Erlotinib.
3. how to take erlotinib
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Route of administration : Oral use.
The tablet should be taken at least one hour before or two hours after the ingestion of food.
The usual dose is one tablet of Erlotinib 150 mg each day if you have non-small cell lung cancer.
The usual dose is one tablet of Erlotinib 100 mg each day if you have metastatic pancreatic cancer. Erlotinib is given in combination with gemcitabine treatment.
Your doctor may adjust your dose in 50 mg steps. For the different dose regimens Erlotinib is available in strengths of 25 mg, 100 mg or 150 mg.
If you take more Erlotinib than you should
Contact your doctor or pharmacist immediately.
You may have increased side effects and your doctor may interrupt your treatment.
If you forget to take Erlotinib
If you miss one or more doses of Erlotinib, contact your doctor or pharmacist as soon as possible.
Do not take a double dose to make up for a forgotten dose.
If you stop taking Erlotinib
It is important to keep taking Erlotinib every day, as long as your doctor prescribes it for you.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Version: 02
Leaflet size: 180 × 420 mm
Font Name: TIMES NEW ROMAN
Font Size : 9pt.(Text matter) 12pt.(Heading)
Pharma Code: front: 1259 Back: 1260
Supersed SAP Code: 2061990
llllllllll
1259
llllllllll
1260
4. possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor as soon as possible if you suffer from any of the below side effects. In some cases your doctor may need to reduce your dose of Erlotinib or interrupt treatment:
- Diarrhoea and vomiting (very common: may affect more than 1 out of 10 people). Persistent and severe diarrhoea may lead to low blood potassium and impairment of your kidney function, particularly if you receive other chemotherapy treatments at the same time. If you experience more severe or persistent diarrhoea contact your doctor immediately as your doctor may need to treat you in the hospital.
- Eye irritation due to conjunctivitis/keratoconjunctivitis (very common: may affect more than 1 out of 10 people) and keratitis (common: may affect up to 1 in 10 people).
- Form of lung irritation called interstitial lung disease (uncommon in European patients; common in Japanese patients: may affect up to 1 in 100 people in Europe and up to 1 in 10 in Japan). This disease can also be linked to the natural progression of your medical condition and can have a fatal outcome in some cases. If you develop symptoms such as sudden difficulty in breathing associated with cough or fever contact your doctor immediately as you could suffer from this disease. Your doctor may decide to permanently stop your treatment with Erlotinib.
- Gastrointestinal perforations have been observed (uncommon: may affect up to 1 in 100 people). Tell your doctor if you have severe pain in your abdomen. Also, tell your doctor if you had peptic ulcers or diverticular disease in the past, as this may increase this risk.
- In rare cases liver failure was observed (rare: may affect up to 1 in 1,000 people). If your blood tests indicate severe changes in your liver function, your doctor may need to interrupt your treatment.
Very common side effects (may affect more than 1 in 10 people):
- Rash which may occur or worsen in sun exposed areas. If you are exposed to sun, protective clothing, and/or use of sun-screen (e.g. mineral-containing) may be advisable
- Infection
- Loss of appetite, decreased weight
- Depression
- Headache, altered skin sensation or numbness in the extremities
- Difficulty in breathing, cough
- Nausea
- Mouth irritation
- Stomach pain, indigestion and flatulence
- Abnormal blood tests for the liver function
- Itching, dry skin and loss of hair
- Tiredness, fever, rigors
Common side effects (may affect up to 1 in 10 people):
- Bleeding from the nose
- Bleeding from the stomach or the intestines
- Inflammatory reactions around the fingernail
- Infection of hair follicles
- Acne
- Cracked skin (skin fissures)
- Reduced kidney function (when given outside the approved indications in combination with chemotherapy)
Uncommon side effects (may affect up to 1 in 100 people):
- Eyelash changes
- Excess body and facial hair of a male distribution pattern
- Eyebrow changes
- Brittle and loose nails
Rare side effects (may affect up to 1 in 1,000 people):
- Flushed or painful palms or soles (Palmar plantar erythrodysaesthesia syndrome)
Very rare side effects (may affect up to 1 in 10,000 people):
- Cases of perforation or ulceration of the cornea
- Severe blistering or peeling of skin (suggestive of Stevens-Johnson syndrome)
- Inflammation of the coloured part of the eye
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
5. how to store erlotinib
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. contents of the pack and other informationwhat erlotinib contains: the active substance is erlotinib. each film-coated tablet contains 25 mg, 100 mg or 150 mg of erlotinib (as erlotinib hydrochloride) depending on the strength.
- The other ingredients are:
What Erlotinib looks like and contents of the pack:
Erlotinib 25 mg is supplied as a white, round, film-coated tablet with ‚H‘ on one side and ‚28‘ on the other side and is available in pack sizes of 30 tablets.
Erlotinib 100 mg is supplied as a white, round, film-coated tablet with ‚H‘ on one side and ‚21‘ on the other side and is available in pack sizes of 30 tablets.
Erlotinib 150 mg is supplied as a white, round, film-coated tablet with ‚H‘ on one side and ‚22‘ on the other side and is available in pack sizes of 30 tablets.
Marketing Authorisation Holder
Amarox Limited
Congress House, 14 Lyon Road
Harrow, Middlesex HA1 2EN
United Kingdom
Manufacturer
Pharmadox Healthcare Ltd
KW20A Kordin Industrial Park
Paola, PLA 3000
Malta
or
Amarox Limited
Congress House, 14 Lyon Road
Harrow, Middlesex HA1 2EN
United Kingdom
This medicinal product is authorised in the Member States of the EEA under the following names:
Germany: Erlotinib Amarox 25 mg Filmtabletten
Erlotinib Amarox 100 mg Filmtabletten
Erlotinib Amarox 150 mg Filmtabletten
The Netherlands: Erlotinib Amarox 25 mg filmomhulde tabletten
Erlotinib Amarox 100 mg filmomhulde tabletten
Erlotinib Amarox 150 mg filmomhulde tabletten
Spain: Erlotinib Tarbis 25 mg comprimodos
recubiertos con peHcula EFG
Erlotinib Tarbis 100 mg comprimodos recubiertos con peHcula EFG
Erlotinib Tarbis 150 mg comprimodos recubiertos con peHcula EFG
United Kingdom: Erlotinib 25 mg film-coated tablets
Erlotinib 100 mg film-coated tablets
Erlotinib 150 mg film-coated tablets
This leaflet was last revised in 08.2021.
2062563